A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome ...

The Covid-19 outbreak in 2020 was on a scale not seen since the Spanish flu pandemic in 1918 and laid bare our lack of ...

Autoimmune diseases represent a significant challenge in the field of medicine, as they occur when the immune system erroneously targets the body's own ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

A novel wireless photothermal DBS nanosystem uses nanoparticles to target and restore damaged neurons in Parkinson’s disease, ...

Skeletal muscle fat infiltration (IMAT) is linked to coronary microvascular dysfunction and increased cardiovascular risk, ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach has ...